- Research works
- 2 ▲ 900% vs 2013–17
- Citations
- 27 14.4 per fractional work
- Top-10% rate
- 100.0% record average 16.5%
- Open access
- 73% world 28%
Not ranked overall: Pulmokine (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Pulmokine (United States) publish most on?
By volume in 2022–2025: Pulmonary Hypertension Research and Treatments, Chronic Obstructive Pulmonary Disease (COPD) Research and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Pulmonary Hypertension Research and Treatments Pulmonary and Respiratory Medicine 0 works
- 2 Chronic Obstructive Pulmonary Disease (COPD) Research Pulmonary and Respiratory Medicine 0 works
- 3 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
How has Pulmokine (United States)'s research output changed?
Output in 2018–2022 was 900% higher than in 2013–2017.
Other research institutions in Rensselaer
- Neural Stem Cell Institute
- New York State Office of Children and Family Services
- Healthcare Association of New York State
- Ultradian Diagnostics (United States)
- SyntheZyme (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.